Pfizer-BioNTech, Moderna, Janssen vaccines highly effective for preventing COVID-19-linked hospitalization
TUESDAY, Aug. 10, 2021 (HealthDay News) — The Pfizer-BioNTech, Moderna, and Janssen COVID-19 vaccines are highly effective for preventing COVID-19-associated hospitalization among older adults in the United States, according to research published in the Aug. 6 early-release issue of the U.S. Centers for Disease Control and Prevention Morbidity and Mortality Weekly Report.
Heidi L. Moline, M.D., from the CDC COVID-19 Response Team, and colleagues examined the real-world effectiveness of the three currently authorized COVID-19 vaccines among individuals aged 65 years and older during Feb. 1 to April 30, 2021. Data from 7,280 patients from the COVID-19-Associated Hospitalization Surveillance Network were analyzed with vaccination coverage data.
The researchers found that the effectiveness of full vaccination in preventing COVID-19-associated hospitalization was 96, 96, and 84 percent for the Pfizer-BioNTech, Moderna, and Janssen vaccine products, respectively, among adults aged 65 to 74 years. Among adults aged 75 years or older, the effectiveness of full vaccination in preventing COVID-19-associated hospitalization was 91, 96, and 85 percent, respectively.
“These findings provide additional evidence that available vaccines are highly effective in preventing COVID-19-associated hospitalizations and demonstrate that performance of COVID-19 vaccines can be assessed using existing disease surveillance and immunization data,” the authors write. “Efforts to increase vaccination coverage are critical to reducing the risk for COVID-19-related hospitalization, particularly in older adults.”
Several authors disclosed financial ties to the pharmaceutical industry.
Lower Cognitive Functioning During 60s Linked to Subsequent Stroke Risk
Polypharmacy of Prescription Medications Increased for U.S. Older Adults
Nearly 1 in 10 Older Adults Used Cannabis in the Past Year
Pharmacist-Led Med Review Improves Medication Quality in Older Patients With Cancer
Most Specialty Oral Anticancer Meds for Blood Cancers Are Initially Rejected by Insurers
Personalized Support Boosts Families" Genetic Testing for Hereditary Cancers
Cancer Survivors Have Lower Levels of Physical Activity
Lower Vertebral Bone Mineral Density Linked to Cognitive Decline